Multicancer Early Detection Screening Tools: Not Economically Efficient, Not Ethically Equitable, Marginally...

Area of Science:

• Oncology
• Health Economics
• Medical Ethics

Background:

• Multi-cancer early detection (MCED) tests aim to screen for numerous cancers simultaneously.
• The Galleri test is a prominent MCED test claiming significant benefits in lives saved and reduced healthcare costs.
• Assessing the medical, economic, and ethical implications of widespread MCED test adoption is crucial.

Purpose of the Study:

• To critically evaluate the claims made for the Galleri test.
• To assess the clinical validity and utility of the Galleri test.
• To analyze the economic and ethical feasibility of public funding for the Galleri test.

Main Methods:

• Critical review of existing literature and data on the Galleri test.
• Medical assessment of diagnostic accuracy, clinical validity, and utility.
• Economic analysis of public funding, including cost-effectiveness and opportunity costs.
• Ethical evaluation of equity and impact on vulnerable populations.

Main Results:

• The Galleri test currently lacks demonstrated clinical validity and clinical utility.
• Widespread public funding of $100 billion annually for the Galleri test is deemed socially unaffordable.
• Significant ethical and economic concerns exist regarding opportunity costs and potential exacerbation of health disparities.

Conclusions:

• The Galleri test does not meet the criteria for clinical validity or utility.
• Public funding for the Galleri test is not economically or ethically justifiable at this time.
• The potential negative impact on cancer care for the least well-off necessitates careful consideration before public funding.